Forward-Focused Oncology: Applying Lessons Learned from COVID to Strengthen Oncology Clinical Trials

The COVID pandemic has had a tremendous impact on clinical development. This is reflected in a decrease in the number of new oncology clinical trials launched, as well as a drop in the number of patients who enrolled in trials. The conduct of oncology clinical trials changed as well, pivoting to ensure the safety of patients, clinical researchers and staff, and adjusting for major travel restrictions. However, the disruption resulted in the opportunity for a change in how clinical trials are conducted – a change that had been long discussed but not put into action. How will oncology clinical trials be strengthened as a result?

Register for this webinar to join Synteract’s Deb Kientop, Vice President, Strategic Development, Oncology, for an insightful webinar on Forward-Focused Oncology: Applying Lessons Learned from COVID to Strengthen Oncology Clinical Trials on April 27, 2021 at 11AM EDT.

This webinar will explore how to develop oncology trials that reflect these positive trends, such as:

• Methods to increase the focus on patient centricity when developing protocols, including education with patient advocacy organizations and patient communities
• Looking beyond academic medical centers to conduct clinical trials, such as using community sites, home health and more
• How to anticipate a realistic approach toward incorporating new technologies
• Understanding operational factors in the new environment, such as site management and data collection and cleaning

After the webinar, participants will have a stronger strategy for tackling oncology studies that will keep their trials running in the post-pandemic environment.

Speaker

Deb Kientop, Vice President, Strategic Development, Oncology, Synteract

Deb Kientop, MBA brings over 25 years of experience in oncology drug development, starting in the cancer research labs at the University of Wisconsin, and moving into business development, medical affairs and clinical development roles within pharma and CRO. Her career has included thought leader engagement, product lifecycle planning, strategy development and execution for proposals and bid defenses, and corporate strategy and alliance management. Through her work with oncology investigators and patient advocacy organizations, she has been able to incorporate insights into patient-centric development strategies. Deb is also a published author and cancer patient advocate.

Prior to joining Synteract, Deb was the Vice President of Life Sciences at Inteliquet, a healthcare technology company. Previously, she held senior director strategy positions at two large CROs, as well as numerous biopharmaceutical organizations including MedImmune, MGI Pharma and Eisai.

Deb holds a Bachelor of Science in Pharmacology and Toxicology, and a Master of Business Administration from the University of Wisconsin.

Message Presenter